Abstract Background Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease characterised by decline in lung function. We evaluated trajectories of forced vital capacity (FVC) and diffusing capacity (DLco) in a cohort of patients with IPF. Methods Patients with IPF that was diagnosed or confirmed at the enrolling centre in the previous 6 months were enrolled into the IPF-PRO Registry between June 2014 and October 2018. Patients were followed prospectively, with lung function data collected as part of routine clinical care. Mean trajectories of FVC and DLco % predicted in all patients and in subgroups by characteristics assessed at enrolment were estimated using a joint model that accounted for factors such a...
International audienceIn patients with chronic fibrosing interstitial lung disease (ILD), a progress...
Abstract Background Many types of interstitial lung diseases (ILDs) may transition to progressive ch...
After introduction of the new international guidelines on idiopathic pulmonary fibrosis (IPF) in 201...
Background: Idiopathic Pulmonary Fibrosis (IPF) is a progressive fibrotic lung disease with a variab...
Proposed criteria for progressive fibrosing interstitial lung disease (PF-ILD) have been linked to i...
Idiopathic pulmonary fibrosis (IPF) is progressive and irreversible. Some discrepancies about IPF st...
Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease that is, by definition,...
Abstract Background Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal fibrosing lung di...
BackgroundFibrotic interstitial lung disease (ILD) is often associated with poor outcomes, but has f...
Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease that is, by definition,...
Idiopathic pulmonary fibrosis (IPF) is a progressive disease associated with decline in lung functio...
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal fibrosing lung disease of...
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal fibrosing lung disease of...
Objective: There is a paucity of observational data on antifibrotic therapy for idiopathic pulmonary...
<div><p>The clinical course in idiopathic pulmonary fibrosis (IPF) is highly heterogeneous, with som...
International audienceIn patients with chronic fibrosing interstitial lung disease (ILD), a progress...
Abstract Background Many types of interstitial lung diseases (ILDs) may transition to progressive ch...
After introduction of the new international guidelines on idiopathic pulmonary fibrosis (IPF) in 201...
Background: Idiopathic Pulmonary Fibrosis (IPF) is a progressive fibrotic lung disease with a variab...
Proposed criteria for progressive fibrosing interstitial lung disease (PF-ILD) have been linked to i...
Idiopathic pulmonary fibrosis (IPF) is progressive and irreversible. Some discrepancies about IPF st...
Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease that is, by definition,...
Abstract Background Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal fibrosing lung di...
BackgroundFibrotic interstitial lung disease (ILD) is often associated with poor outcomes, but has f...
Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease that is, by definition,...
Idiopathic pulmonary fibrosis (IPF) is a progressive disease associated with decline in lung functio...
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal fibrosing lung disease of...
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal fibrosing lung disease of...
Objective: There is a paucity of observational data on antifibrotic therapy for idiopathic pulmonary...
<div><p>The clinical course in idiopathic pulmonary fibrosis (IPF) is highly heterogeneous, with som...
International audienceIn patients with chronic fibrosing interstitial lung disease (ILD), a progress...
Abstract Background Many types of interstitial lung diseases (ILDs) may transition to progressive ch...
After introduction of the new international guidelines on idiopathic pulmonary fibrosis (IPF) in 201...